1607444-04-1

Basic information

• Product Name: [3-(3-carbamoylphenyl)phenyl] N-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl] carbamate
• CAS NO: 1607444-04-1
• Molecular Weight: 541.477
• Mol File: 1607444-04-1.mol

Chemical Properties

• CAS DataBase Reference: [3-(3-carbamoylphenyl)phenyl] N-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl] carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: [3-(3-carbamoylphenyl)phenyl] N-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl] carbamate(1607444-04-1)
• EPA Substance Registry System: [3-(3-carbamoylphenyl)phenyl] N-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl] carbamate(1607444-04-1)

Safety Data

• Hazardous Substances Data: 1607444-04-1(Hazardous Substances Data)

Upstream product

• 580-51-8 [1,1'-biphenyl]-3-ol 
• 591-20-8 3-Bromophenol 
• 98-80-6 phenylboronic acid 
• 351422-73-6 (3-(aminocarbonyl)phenyl)boronic acid 
• 189061-44-7 4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butylamine 
• 367275-36-3 2-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}-1H-isoindole-1,3(2H)-dione 
• 119532-26-2 1-(2,3-dichlorophenyl)-piperazine hydrochloride 
• 681161-44-4 3′-hydroxy-(1,1′-biphenyl)-3-carboxamide 

Relevant articles and documents

Design, Synthesis, Structure-Activity Relationship Studies, and Three-Dimensional Quantitative Structure-Activity Relationship (3D-QSAR) Modeling of a Series of O-Biphenyl Carbamates as Dual Modulators of Dopamine D3 Receptor and Fatty Acid Amide Hydrolase

We recently reported molecules designed according to the multitarget-directed ligand paradigm to exert combined activity at human fatty acid amide hydrolase (FAAH) and dopamine receptor subtype D3 (D3R). Both targets are relevant for tackling several types of addiction (most notably nicotine addiction) and other compulsive behaviors. Here, we report an SAR exploration of a series of biphenyl-N-[4-[4-(2,3-substituted-phenyl)piperazine-1-yl]alkyl]carbamates, a novel class of molecules that had shown promising activities at the FAAH-D3R target combination in preliminary studies. We have rationalized the structural features conducive to activities at the main targets and investigated activities at two off-targets: dopamine receptor subtype D2 and endocannabinoid receptor CB1. To understand the unexpected affinity for the CB1 receptor, we devised a 3D-QSAR model, which we then prospectively validated. Compound 33 was selected for PK studies because it displayed balanced affinities for the main targets and clear selectivity over the two off-targets. 33 has good stability and oral bioavailability and can cross the blood-brain barrier.

PHENYL CARBAMATES AND THEIR USE AS INHIBITORS OF THE FATTY ACID AMIDE HYDROLASE (FAAH) ENZYME AND MODULATORS OF THE D3 DOPAMINE RECEPTOR (D3DR)

The invention provides compounds of Formula (I) or pharmaceutically acceptable salts thereof wherein Ar', R1, R2, R3, R4, X, Y are as defined in the description of invention, as multi-target directed ligands (MT

Applying a multitarget rational drug design strategy: The first set of modulators with potent and balanced activity toward dopamine D3 receptor and fatty acid amide hydrolase

Combining computer-assisted drug design and synthetic efforts, we generated compounds with potent and balanced activities toward both D3 dopamine receptor and fatty acid amide hydrolase (FAAH) enzyme. By concurrently modulating these targets, our compounds hold great potential toward exerting a disease-modifying effect on nicotine addiction and other forms of compulsive behavior.